OMICS International

International Conferences

Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series Ltd: World’s leading Event Organizer

 

Demyelinating Drugs


As per available reports about 43 relevant Journals, 41 Conferences  are presently dedicated exclusively to Demyelinating Drugs and about 798 articles are being published on Demyelinating Drugs .

Drugs and their interactions may contribute in part or fully to the neurological demyelination, and treatment response may assist diagnostically or in future management plans. Rarely, immune-mediated demyelinating neuropathies occur during initial or maintenance treatment with immunomodulatory, immunosuppressive or antineoplastic agents. Medication-induced immune perturbation presumably triggers a dysimmune attack directed at unidentified peripheral nerve myelin epitopes; true peripheral nerve toxicity (i.e., dependent on accumulative dose or serum level) plays no identified role. Biomechanics In Organs, Biofluid mechanics, Biotribology are the wings included in  Pharmacological and Toxicological Sciences including subtopics Molecular and Cellular Pharmacology, Pharmacogenomics and Pharmacoepidemiology, Clinical pharmacology, Immunology¸ and  Cardiovascular pharmacology.

OMICS International Organizes 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide.

Scope and Importance:

Chronic inflammatory demyelinating polyradiculoneuropathy (cidP) is a term for a group of acquired, immune-mediated inflammatory demyelinating disorders of the peripheral nervous system. Most patients with cidP respond to ‘first-line’ therapy with intravenous immunoglobulin (iViG), plasmapheresis and/or corticosteroids. ‘conventional’ immunosuppressive drugs are of no proven benefit. Biological agents directed at key aspects of the cidP immunopathogenic pathway have gained increasing attention due to the unpredictable efficacy and overall health risks of non-targeted immunosuppressive drugs. Presently, there exists insufficient clinical experience with biological therapy to allow specific treatment recommendations for cidP. The challenge remains to identify drug-naïve or treatment-resistant cidP patients who will most likely respond to targeted immunotherapy. 

Drug-induced peripheral neurotoxicity usually manifests as a length-dependent, "dying back" axonal, predominantly sensory polyneuropathy. Rarely, immune-mediated demyelinating neuropathies occur during initial or maintenance treatment with immunomodulatory, immunosuppressive or antineoplastic agents. Medication-induced immune perturbation presumably triggers a dysimmune attack directed at unidentified peripheral nerve myelin epitopes; true peripheral nerve toxicity (i.e., dependent on accumulative dose or serum level) plays no identified role.

Several neuroimaging studies have revealed that the brains of schizophrenic patients exhibit abnormalities in white matter pathways. Using magnetic resonance imaging (MRI) methods, such as T2-weighted imaging and diffusion tensor imaging (DTI), it is possible to objectively quantify white matter structural properties in patients as well as the pharmacological effect on white matter. In the preclinical domain, these strategies, however, have been hindered by a lack of in vivo imaging assays. Mainly demyelination diseases are due to medications uncommonly prescribed not used in the U.S(perhexline,almitrine), normally used in low doses with minimal toxicity(phenytoin,ara-c), or typically used for short duration(metronidazole).A number of other factors render some individuals more vulnerable to potentially toxic medications.

Market Analysis:

The global market for treatments for syndromes of neurological disorders was valued at 10.5 billion in 2011 and should reach $11.1 billion in 2012. Total market value is expected to reach $16.7 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 8.5%.

The global sales of drugs to treat progressive dementia with other neurological abnormalities expected to reach $537.2 million in 2012 and $913.7 million by 2017, at a CAGR of 11.2% over the five-year forecast period.

International symposium and workshops

List of Best International Conferences:

  1. 8th Pharmaceutics and Novel Drug Delivery Systems Conference
    March 07-09, 2016 Madrid, Spain
  2. Industrial Pharmacy Conference
    April 28-29, 2016 Dubai, UAE
  3. 4th Medicinal Chemistry and Computer Aided Drug Designing Conference
    December 01-03, 2016 Chicago, USA
  4. 2nd Parenterals and Injectables Conference
    October 24-26, 2016 Istanbul, Turkey
  5. 4th Clinical Pharmacy Conference
    Oct 31 - Nov 01, 2016 Las Vegas, USA
  6. 2nd Drug Discovery and Designing Conference
    Oct 31-Nov 02, 2016 Istanbul, Turkey
  7. 4th Neuropharmacology Conference
    September 15-17, 2016 San Antonio, USA
  8. 7th Pharmacovigilance and Clinical Trials Conference
    September 19-21, 2016 Vienna, Austria
  9. 6th Pharmacovigilance Congress
    August 01-03, 2016 Toronto, Canada
  10. 3rd Pharmacology Congress
    August 08-10, 2016 Birmingham, UK
  11. 6th Annual Drug Delivery & Formulation Americas Summit
    April 14-15, 2016 Costa Mesa, CA, US
  12. 18th International Conference on Pharmaceutical Sciences & Pharmacology
    January 21 - 22, 2016, Paris, France
  13. American Society for Clinical Pharmacology & Therapeutics Annual Meeting
    March 9-12, 2016, California, United States
  14. 7th Annual Global Drug Delivery & Formulation Summit
    May 23-25, 2016 Dusseldorf, Germany
  15. Drug Delivery Partnerships 2016 (DDP 2016)
    January 20-22, 2016 Palm Beach Gardens, FL, US
  16. Peptide Drug Design & Delivery Summit
    February 24-25, 2016 San Francisco, CA, US   

Relevant Society and Associations

Companies

This page will be updated regularly.

This page was last updated on 11th Sep, 2015

Conferenceseries Destinations

Contact Us

Medical Conferences
Jessie Grace
jessie.grace@conferenceseries.com
1-702-508-5200 Ext:8031, 8041

Pharmaceutical Conferences
Badoni Victor
badoni.victor@conferenceseries.com
1-702-508-5200 Ext:8045, 8047

Immunology & Microbiology Conferences
Walker Smith
walker.smith@conferenceseries.com
1-702-508-5200 Ext:8031

Cancer Conferences
Raul Cliff
raul.cliff@conferenceseries.com
1-702-508-5200 Ext:8039

Nursing and Healthcare Conferences
Jennifer Leny
jennifer.leny@conferenceseries.com
1-702-508-5200 Ext:8044

Diabetes Conferences
Stanley knight
stanley.knight@conferenceseries.com
1-702-508-5200 Ext:8040

Neuroscience Conferences
Sandeep Kumar
sandeep@conferenceseries.com
1-702-508-5200 Ext:8034

Dental Conferences
Raul Cliff
raul.cliff@conferenceseries.com
1-702-508-5200 Ext:8039

Clinical and Biochemistry Conferences
Rohit Casper
rohit.casper@conferenceseries.com
1-702-508-5200 Ext:8033

Biotechnology Conferences
Ravi Vittal
ravi.vittal@conferenceseries.com
1-702-508-5200 Ext:8031, 8037

Material Science Conferences
Lucy Grey
lucygrey@conferenceseries.com
1-702-508-5200 Ext:8035

Genetics & Mol Biology Conferences
Stephen Bruce
stephen.bruce@conferenceseries.com
1-702-508-5200 Ext:8038

Engineering Conferences
Dolly A
dolly@conferenceseries.com
+1-702-508-5200 Ext:8051

Program Enquiries
Symposia/Workshops
Sponsorships
Media Partners | Advertising